Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 11 - 20 of about 91   

Articles published

CBST 63.95 +0.02 (0.03%)
price chart
Volatile Movements-Cubist Pharmaceuticals Inc (CBST), Microvision, Inc. (MVIS ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) decreased -4.97% and closed at $70.35 on a traded volume of 1.13 million shares, in comparison to 753,707.00 shares of average trading volume.
Cubist Pharmaceuticals Rating Reiterated by Aegis (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST)'s stock had its �buy� rating reaffirmed by equities research analysts at Aegis in a research note issued to investors on Tuesday, American Banking and Market News reports.
Cubist Pharmaceuticals PT Raised to $73.00 at Cantor Fitzgerald (CBST)  Ticker Report
Cubist Pharma (CBST) SIVEXTRO Approval Outlook Improves; Aegis Maintains ...  StreetInsider.com (subscription)
Related articles »  
Why MannKind (MNKD) is Outpacing these Biotech Stocks, Questcor ...
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) shares moved up 2% after the company reported that it would issue its first quarter 2014 financial results at 4:00 p.m.
Related articles »  
Cubist Pharmaceuticals Price Target Raised to $73.00 at Cantor Fitzgerald (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST) had its price target increased by Cantor Fitzgerald to $73.00 in a research report sent to investors on Thursday morning, StockRatingsNetwork.
Cantor Fitzgerald Increases Cubist Pharmaceuticals Price Target to $73.00 (CBST)  Zolmax
Related articles »  
Cubist Rises on Favorable FDA Panel View
Shares of Cubist Pharmaceuticals, Inc. (CBST) climbed more than 4% to $73.15 per share on Mar 31, 2014 following the favorable recommendation of an advisory panel of the Food and Drug Administration (:FDA) on the company's candidate tedizolid ...
FDA panel votes in favor of two anti-infective drugs
The panel voted unanimously that Cubist Pharmaceuticals Inc's tedizolid and Durata Therapeutics Inc's dalbavancin showed substantial evidence of safety and efficacy.
Cubist's (CBST) SIVEXTRO Receives Unanimous FDA Committee ...  StreetInsider.com (subscription)
Related articles »  
Cubist Pharmaceuticals (CBST) Marked As Today's Roof Leaker Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Cubist Pharmaceuticals ...
The Deal Reveals Candidates for Seventh Annual Most Admired Corporate ...
-Financial Category: Arthur J. Gallagher & Co. , White Mountains Insurance Group , Morgan Stanley. -Healthcare Category: Amgen Inc. , Valeant Pharmaceuticals International Inc. , Perrigo Co.
Biotech stock pullback good for industry
That includes many of the best-known biotech names in Massachusetts, companies like Biogen Idec Inc., Vertex Pharmaceuticals Inc., and Cubist Pharmaceuticals Inc. The move also shook up the pipeline of up- and-coming life sciences companies looking to ...
Related articles »  
Hottest Healthcare Stocks Now � CNMD EXAS ACAD NKTR
Acadia Pharmaceuticals Inc (ACAD): ACAD stock is up 3.0% today on 3 times normal volume. Nektar Therapeutics (NKTR): NKTR stock is up ... Actavis Inc (ACT): ACT stock is up 2.6% today. Cubist Pharmaceuticals (CBST): CBST stock is up 2.5% today.